Coherus Announces Appointment of George G. Montgomery as Chief Financial Officer


Coherus Announces Appointment of George G. Montgomery as Chief Financial Officer

REDWOOD CITY, CA (October 17th, 2012) – Coherus Biosciences, Inc. ("Coherus"), a biopharmaceuticals company dedicated to global development and commercialization of biologic therapeutics, announced today that it has appointed George G. Montgomery as Chief Financial Officer. Mr. Montgomery joins Coherus with over 25 years of experience as an investment banker and industry executive in the pharmaceutical and biotechnology sectors.

"George has been contributing to Coherus' success from early on in the company's development. He was instrumental in helping us raise our first institutional round of financing, as well as complete our licensing arrangement with Daiichi Sankyo," said Denny Lanfear, Chief Executive Officer of Coherus. "George has a renowned reputation in the industry as a premier investment banker and strategic advisor for biotech companies. We are thrilled and fortunate to have him join Coherus as CFO, and work with us to move the company's strategic agenda forward."

"Coherus has a unique business and global commercialization model specifically addressing the enormous biosimilar opportunity. Working with the company for the past eighteen months convinced me that all the key factors for success are in place." said Mr. Montgomery. "I am excited to work with the outstanding team at Coherus to help achieve the company's full potential."

Mr. Montgomery joins Coherus with over 25 years experience in investment banking and healthcare industry leadership. Over his career, he has focused on private and public financings, M&A advisory work, divestitures and negotiating strategic partnerships. Most recently, Mr. Montgomery was a Managing Director at Sagent Advisors, LLC. Prior to Sagent, he served as a Managing Director at Montgomery & Co., LLC where he led the firm's healthcare effort and helped open their San Francisco office. During his tenure there, he also served on their Board of Directors and was a member of the executive committee. Prior to Montgomery & Co., he was a Managing Director at JP Morgan H&Q where he led the firm's healthcare efforts on the West Coast. He has also been a Managing Director at Cowen & Company and started his career at Credit Suisse First Boston in 1983. George received his MBA from the Wharton School at the University of Pennsylvania and his BA from Yale College.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics. Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases. Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

Coherus Media Contact: [email protected]om
 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.